MINORITY-BASED COMMUNITY ONCOLOGY PROGRAM

基于蒙特菲奥雷-爱因斯坦少数民族的NCORP社区网站的总体目标是推动 参与NCORP对早期和晚期癌症的诊断、预防和治疗 审判作为少数族裔/服务不足的社区网站，并在科学和管理上为 NCORP研究基地。这将通过利用Montefiore Health的优势来实现 系统(MHS)，包括Montefiore医疗中心(MMC)，为综合患者带来优势 学术医疗中心的护理和创新医疗保健提供系统，主要服务于 少数族裔人口，以及阿尔伯特·爱因斯坦医学院和癌症中心(爱因斯坦) 通过其NCI在培训和教育以及Baslc、翻译和临床研究方面带来优势- 指定的癌症中心。MMC-爱因斯坦计划也为NCORP带来了关键的领导能力 研究基地，包括ECOG-ACRIN、联盟和NRG，包括在 小组主席办公室、科学委员会主席(或联席主席)、礼宾主席(或联席主席)。我们的计划 作为癌症研究的主要成员，我们长期参与癌症研究的各个方面 ECOG 45年和NCI指定的癌症中心48年，以及强大的少数民族历史 癌症治疗试验的收益(约占所有患者的65%)。MMC为布朗克斯服务，这是一个 147万居民，其中89%是少数族裔，29%生活在联邦贫困线以下。在 在之前的资助期间，我们对NCORP研究基地的科学贡献有着良好的记录，以及 在极大的少数股东参与下实现了我们的应计目标。在下一个资助期，我们将 继续我们在癌症治疗领域的强大领导地位(EA2165)，将我们的活动范围扩大到 包括癌症成像和筛查(TMIST)、癌症控制/预防(EAZ171)和 癌症护理服务研究(CCDR)。MMC-爱因斯坦NCORP计划由教师领导， 在癌症治疗和生物标记物研究(医学博士J·斯帕拉诺)、精确医学和 免疫肿瘤学(B.Halmos，MD)和CCDR和癌症预防/控制(B.Rapkin，PhD)，以及 在具有广泛专业知识的其他调查人员的支持下，其中一些人受益于NCI- 资助临床癌症研究的K12培训计划。

The overall goals of the Montefiore-Einstein minority-based NCORP community site are to advance the diagnosis, prevention, and management of early and advanced cancer by participating in NCORP trials as a minority/underserved community site, and contributing scientifically and administratively to the NCORP research bases. This will be accomplished by leveraging the strengths of the Montefiore Health System (MHS), including Montefiore Medical Center (MMC), which brings strengths in integrated patient care and innovative health care delivery systems in an academic medical center serving a largely minority population, and the Albert Einstein College of Medicine and Cancer Center (Einstein), which brings strength in training and education, and in baslc, translational, and clinical research through its NCI- designated cancer center. The MMC-Einstein program also brings critical leadership to the NCORP Research Bases, including ECOG-ACRIN, Alliance, and NRG, including leadership roles at the level of the group chair's office, scientific committee chair (or co-chair), and protocol chair (or co-chair). Our plans build upon our long-standing involvement in all aspects of cancer research as a main member of ECOG for 45 years and an NCI-designated cancer center for 48 years, and a strong history of minority accrual to cancer treatment trials (about 65%of all patients). MMC serves the Bronx, an urban community of 1.47 million residents, of whom 89% are minorities and 29% live below the federal poverty level. In the prior funding period we had a strong track record scientific contributions to the NCORP research bases, and met our accrual targets with exceptionally strong minority participation. In the next funding period, we will continue our strong leadership in cancer therapeutics (EA2165), expand the spectrum of our activities to include new programs in cancer imaging and screening (TMIST), cancer control/prevention (EAZ171), and cancer care delivery research (CCDR). The MMC-Einstein NCORP program is led by faculty with experience in cancer therapeutics and biomarker research (J. Sparano, MD), precision medicine and immunoncology (B. Halmos, MD), and CCDR and cancer prevention/control (B. Rapkin, PhD), and is supported by a cadre of other investigators with a broad range of expertise, some of whom benefited from NCI- funded K12 training program in clinical cancer research.